GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » Sale Of Investment

Bavarian Nordic A/S (Bavarian Nordic A/S) Sale Of Investment : $191.7 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Bavarian Nordic A/S Sale Of Investment?

Bavarian Nordic A/S's sale of investment for the three months ended in Mar. 2024 was $0.8 Mil. It means Bavarian Nordic A/S gained $0.8 Mil from selling investments. Bavarian Nordic A/S's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was $191.7 Mil.

Compared with last quarter ($13.9 Mil in Dec. 2023 ), Bavarian Nordic A/S gained less money from selling investments in Mar. 2024 ($0.8 Mil).


Bavarian Nordic A/S Sale Of Investment Historical Data

The historical data trend for Bavarian Nordic A/S's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S Sale Of Investment Chart

Bavarian Nordic A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 461.15 186.69 51.11 154.96 279.88

Bavarian Nordic A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.37 165.92 11.11 13.86 0.82

Bavarian Nordic A/S Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $191.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bavarian Nordic A/S Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Bavarian Nordic A/S (Bavarian Nordic A/S) Business Description

Traded in Other Exchanges
Address
Philip Heymans Alle 3, Hellerup, DNK, DK-2900
Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.

Bavarian Nordic A/S (Bavarian Nordic A/S) Headlines

From GuruFocus

Q3 2021 Bavarian Nordic A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2022 Bavarian Nordic A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2019 Bavarian Nordic A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2022 Bavarian Nordic A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024

Bavarian Nordic A/S - Special Call Transcript

By GuruFocus Research 02-13-2024

Q1 2021 Bavarian Nordic A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024